Taxol as Second-Line Therapy in Recurrent Breast and Ovarian Cancer
R. Borovik, M. Steiner, J. Atad, B. Sneiderman, T. Rosenberg, S. Palti
Oncology Depts., Lin Medical Center and Carmel Medical Center, Haifa
Results of chemotherapy with Taxol (paclitaxel) in 55 patients with recurrent breast and ovarian cancer were reviewed. Taxol was given as a 3-hour infusion, every 3 weeks, on an outpatient basis. There was complete or partial response in 8 patients (23%) with breast cancer and 10 (50%) with ovarian cancer. Performance status and previous response to adriamycin were important prognostic factors. Toxicity was manageable. Treatment had to be stopped for hypersensitivity reactions in only 2 patients. Taxol given in an ambulatory clinic is safe and effective.